Theriva Biologics, Inc. 8-K

What Happened
Theriva Biologics, Inc. (a Nevada corporation) announced its financial results for the quarter ended March 31, 2026 by issuing a press release on May 5, 2026. The company filed a Current Report on Form 8-K (Item 2.02) to disclose those results and attached the press release as Exhibit 99.1.

Key Details

• Filing date: May 5, 2026; quarter covered: quarter ended March 31, 2026.
• Item reported: 2.02 (Results of Operations and Financial Condition).
• Exhibit attached: 99.1 — the company press release dated May 5, 2026 (also referenced in the 8-K).
• Interactive XBRL cover page is included (Exhibit 104).

Why It Matters
This 8-K makes Theriva’s quarterly financial results publicly available and part of its SEC record. Retail investors should read the attached press release (Exhibit 99.1) for the specific figures on revenue, expenses, profitability, and cash position, since those details drive assessments of near-term performance and valuation. The filing itself is a formal disclosure under Item 2.02; it does not replace full quarterly filings (e.g., Form 10-Q) but gives an immediate, official snapshot of the quarter’s results.